Laurus Labs Limited
Kotak Offshore decreased its stake in Laurus Labs, selling 297,109 shares and reducing its holding from 1.06% to 1.01%.
A research-driven pharmaceutical and biotechnology company specializing in Active Pharmaceutical Ingredients for anti-retroviral, oncology, cardiovascular, and gastroenterology therapies with global leadership positions in select segments. Laurus Labs operates multiple facilities approved by major regulatory agencies including USFDA, WHO-Geneva, EMA, and others. The company provides integrated contract manufacturing and development services to international pharmaceutical innovators across clinical development through commercial production stages.
India FPI activity attributed to Kotak Mahindra group affiliates and offshore funds investing in listed Indian equities.